Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

Clinical resistance to the second-generation antiandrogen enzalutamide in castration resistant prostate cancer (CRPC), despite persistent androgen receptor (AR) activity in tumors, highlights the unmet medical need for next generation antagonists. We have identified and characterized tetra-aryl cycl...

Full description

Bibliographic Details
Main Authors: Pollock, Julie A., Wardell, Suzanne E., Parent, Alexander A., Stagg, David B., Ellison, Stephanie J., Alley, Holly M., Chao, Christina A., Lawrence, Scott A., Stice, James P., Spasojevic, Ivan, Baker, Jennifer G., Kim, Sung Hoon, McDonnell, Donald P., Katzenellenbogen, John A., Norris, John D.
Format: Online
Language:English
Published: 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030124/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030124/

Similar Items